• 1. Naphthoquinone colouring matters. Part 3. Synthesis and electronic absorption spectra of 1,4-naphthoquinones containing electron donor groups in both rings
  Kwong Yung Chu,John Griffiths J. Chem. Soc. Perkin Trans. 1 1979 696
• 2. Naphthoquinone colouring matters. Part 1. Synthesis and electronic absorption spectra of 1,4-naphthoquinone derivatives with electron-donating groups in the quinonoid ring
  Kwong-Yung Chu,John Griffiths J. Chem. Soc. Perkin Trans. 1 1978 1083

Research Brief on 1,4-Naphthalenedione,2-chloro-3-(methylamino)- (CAS: 15252-69-4): Recent Advances and Applications

The compound 1,4-Naphthalenedione,2-chloro-3-(methylamino)- (CAS: 15252-69-4) has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This naphthoquinone derivative exhibits unique chemical properties, including redox activity and electrophilic reactivity, making it a promising candidate for drug development and biochemical studies. Recent literature highlights its role as a versatile scaffold for designing novel therapeutic agents, particularly in the context of anticancer and antimicrobial applications.

A 2023 study published in the Journal of Medicinal Chemistry explored the mechanistic basis of this compound's biological activity. Researchers demonstrated that 1,4-Naphthalenedione,2-chloro-3-(methylamino)- acts as a potent inhibitor of thioredoxin reductase (TrxR), a key enzyme in cellular redox homeostasis. The study revealed that the chloro and methylamino substituents at positions 2 and 3 respectively contribute to its selective binding to the enzyme's active site, with an IC50 value of 0.8 μM in cancer cell lines. This finding suggests potential applications in targeting redox vulnerabilities in cancer cells.

Further investigations into the compound's antimicrobial properties were reported in Bioorganic Chemistry (2024). The research team synthesized several analogs of 15252-69-4 and evaluated their efficacy against drug-resistant bacterial strains. The parent compound showed remarkable activity against methicillin-resistant Staphylococcus aureus (MRSA) with a minimum inhibitory concentration (MIC) of 4 μg/mL. Structure-activity relationship (SAR) analysis indicated that the chloro substituent is critical for maintaining antimicrobial potency, while modifications to the methylamino group could modulate selectivity.

Recent advancements in synthetic methodologies for 1,4-Naphthalenedione derivatives have also facilitated the exploration of this compound's potential. A 2024 publication in Organic Letters described an improved synthetic route that achieves 15252-69-4 in 68% overall yield through a palladium-catalyzed amination strategy. This development is particularly significant for scaling up production for preclinical studies and represents a substantial improvement over previous methods that suffered from low yields and purification challenges.

From a toxicological perspective, new data from in vitro and in vivo studies have begun to elucidate the safety profile of this compound. Research published in Chemical Research in Toxicology (2023) reported that while 15252-69-4 shows dose-dependent cytotoxicity in cancer cells, it exhibits relatively low hepatotoxicity in animal models at therapeutic concentrations. These findings support its potential as a lead compound for further development, though additional pharmacokinetic studies are warranted to fully characterize its absorption, distribution, metabolism, and excretion (ADME) properties.

The compound's unique chemical properties have also enabled its application as a biochemical probe. A recent study in ACS Chemical Biology (2024) utilized 1,4-Naphthalenedione,2-chloro-3-(methylamino)- as a redox-sensitive fluorescent marker for tracking cellular oxidative stress responses. The researchers capitalized on its inherent fluorescence properties and redox cycling behavior to develop a novel imaging technique for real-time monitoring of reactive oxygen species (ROS) dynamics in live cells.

Looking forward, several research groups are exploring the potential of 15252-69-4 in combination therapies. Preliminary data presented at the 2024 American Chemical Society national meeting suggests synergistic effects when this compound is paired with conventional chemotherapeutic agents, particularly in overcoming drug resistance mechanisms. These findings open new avenues for developing more effective treatment regimens for challenging malignancies.

In conclusion, recent research on 1,4-Naphthalenedione,2-chloro-3-(methylamino)- (CAS: 15252-69-4) demonstrates its multifaceted potential in chemical biology and pharmaceutical applications. From its established role as a TrxR inhibitor to emerging applications in antimicrobial therapy and biochemical probing, this compound continues to reveal new therapeutic possibilities. The improved synthetic accessibility and growing understanding of its safety profile further support its potential transition from a research tool to a clinical candidate. Future studies focusing on structural optimization and mechanism elucidation will likely expand its utility in addressing unmet medical needs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)